Biosimilars have been quietly moderating drug prices in the background, Bernstein analyst Ronny Gal said in a recent report. Now, armed with their first biosimilar green light of 2021, Biocon and ...

Natala Constantine, 38, of Philadelphia, Pa. injects herself daily with insulin to stay alive. She says she was diagnosed with type 1 diabetes 13 years ago, and reports Lantus worked well for her.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

CALIFORNIA, USA — Californians with diabetes will soon have access to a low-cost insulin pen as part of a new state initiative announced today, October 16, by Gov. Gavin Newsom. Beginning Jan. 1, 2026 ...